bimagrumab semaglutide Antibody blockade of activin type II receptors preserves skeletal muscle mass and enhances fat loss during GLP-1 receptor agonism 60% HFD Induced Obesity (DIO)

Acetyl GLP-1+GIP supports fat loss and metabolic regulation by mimicking incretin hormones, enhancing insulin sensitivity, and reducing appetite

Third-party tested, COA per batch, shipped in Canada

and the delicate fomnula modifies the appearance of pores.Body-Safe & Comfortable Flexible material, flexible fit with skin movement.Easy to use, suitable for differentscene needs, ensuring gentle yet effective results for all skin types.Safety & totally gentleGood application experience, suitable for a variety of skin conditions,Easy to tear and applyleaving no sticky residue,protects skin and reduces damage.Quick & Convenient ApplicationSMGT-GLP-1Nano Microneedle Patch Fits the skin tightly, stable and not easy to slip,No complicated stepsrequired, just apply directly.Achieve noticeable results in just 15 minutes per week.

Eli Lillys triple agonist demonstrated an average weight loss of 16.8% in a Phase 3 trial for the treatment of type 2 diabetes.

The company is adding new capabilities of Combi-line for Microsphere, additional Bag line and lyos for the Penem block in Pashamylaram facility in Hyderabad and will be earmarking capital for further building on its Biosimilar CDMO facility

WHAT MAKES OUR BLEND DIFFERENT 18 scientifically dosed enzymes Dual protease complex, Bromelain & Papain for thorough protein breakdown Targeted FODMAP relief -Galactosidase tackles gas-forming sugars in beans and lentils